1. Blomme, Arnaud, Peter, Coralie, Mui, Ernest, Zanivan, Sara, Leung, Hing Y. 2022. THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. In EMBO molecular medicine, 14, e14764. doi:10.15252/emmm.202114764. https://pubmed.ncbi.nlm.nih.gov/35014179/
2. Lu, Xingjia, Chen, Wenlin, Tian, Gengzhou, Ge, Fei. 2023. THEM6 is a prognostic biomarker for breast cancer and is associated with immune infiltration. In Scientific reports, 13, 21974. doi:10.1038/s41598-023-49379-5. https://pubmed.ncbi.nlm.nih.gov/38081884/
3. Zhao, Xu, Hu, Jiao, Li, Jiuyi, Yuan, Junbin, Deng, Huiyin. 2022. THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer. In Disease markers, 2022, 7147279. doi:10.1155/2022/7147279. https://pubmed.ncbi.nlm.nih.gov/35909893/
4. Song, Xiao-Qing, Shao, Zhi-Ming. 2024. Identification of immune-related prognostic biomarkers in triple-negative breast cancer. In Translational cancer research, 13, 1707-1720. doi:10.21037/tcr-23-1554. https://pubmed.ncbi.nlm.nih.gov/38737702/